Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMICE study of IVIg in autoimmune epilepsy
NL-OMON56107Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polyvalent human immunoglobulin in autoimmune epilepsy, sponsored by Erasmus MC. Primary endpoints: Responder rate by seizure reduction and Seizure freedom rate. Started Aug 2020; status: recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
autoimmune epilepsy
Beyond the preview
Go deeper on NL-OMON56107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56107.